Skip to main content

Table 1 Susceptibility of XMRV and HIV-1 to reverse transcriptase inhibitors.

From: Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors

Inhibitor classb Inhibitorc EC50(μM)a
   HIV-1NL4-3 XMRVVP62+LtatSNd XMRV22Rv1+LtatSNd
NRTI AZT 0.10 ± 0.05 0.12 ± 0.03 (1) 0.06 ± 0.02 (1)
  AZddG 0.71 ± 0.01 1.1 ± 0.1 (2) 2.7 ± 0.7 (4)
  AZddA 2.0 ± 0.9 1.6 ± 0.4 (1) 3.2 ± 1.2 (2)
  tenofovir 3.5 ± 0.9 5.8 ± 3.2 (2) 5.3 ± 3.8 (2)
  adefovir 14 ± 2 9.5 ± 3.7 (1) 7.0 ± 0.8 (0.5)
  D4T 0.99 ± 0.53 34 ± 22 (34) 13 ± 1 (13)
  ddI 1.79 ± 0.04 43 ± 23 (24) 43 ± 12 (24)
  abacavir 3.6 ± 1.9 94 ± 54 (26) 66 ± 39 (18)
  3TC 0.35 ± 0.07 > 40 (> 100) > 40 (> 100)
  FTC 0.059 ± 0.041 > 40 (> 100) > 40 (> 100)
NNRTI efavirenz 0.005 ± 0.002 > 1 (> 200) > 1 (> 200)
  nevirapine 0.22 ± 0.07 > 4 (> 18) > 4 (> 18)
PPi analog PFA 126 ± 93 > 400 (> 3) > 400 (> 3)
  1. a EC50 values were measured in MAGIC-5A cells as described in Methods and are the means ± standard deviation from two or more independent experiments. Numbers in parentheses indicate the fold change in EC50 relative to HIV-1NL4-3. Values shown in bold are significantly different from the corresponding values for HIV-1NL4-3 (p < 0.05, ANOVA with Tukey's multiple comparison test).
  2. b NRTI, nucleoside reverse transcriptase inhibitor. NNRTI, non-nucleoside reverse transcriptase inhibitor. PPi analog, pyrophosphate analog.
  3. c See Abbreviations for drug names.
  4. d XMRV-pseudotyped LtatSN virus. See text for details.